FDA approves first factor XIa inhibitor for secondary stroke… | HappeningNow.news

Health · 8 views

FDA approves first factor XIa inhibitor for secondary stroke prevention

The U.S.

Source AI Summary Published 1h 25m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 8 Community interest
Brief read Under 1 min brief 92 words

AI Summary

The FDA approved Sunharbo (asundexian) 50 mg tablets for use with antiplatelet therapy to lower stroke risk in adults who have had a recent mild‑to‑moderate noncardioembolic ischemic stroke or a high‑risk transient ischemic attack. Sunharbo is the first factor XIa inhibitor authorized for this purpose. Its effectiveness is reduced when taken with drugs that are combined P‑gp and strong CYP3A4 inducers, so such combinations are not recommended. The drug is also not advised for patients with moderate or severe liver impairment and is not approved for stroke prevention in atrial fibrillation patients.

AI summaries can be wrong sometimes—always verify important details using the source article.

How AI & Automation are used
Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page